(PharmaNewsWire.Com, March 23, 2018 ) Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape
Summary
GBI Research's latest report, "Monoclonal Antibodies-Global Trends in the Competitive, Technological and R&D Landscape" discusses both the pipeline and market shares of Monoclonal Antibodies (mAbs) across a number of therapy areas. mAbs are defined as a collection of antibodies produced from a single B-cell clone. These antibodies therefore share binding specificity towards a certain antigen, and can be used as a means of targeted therapy within a number of indications across the pharmaceutical market.
mAbs have been in development in humans since the mid-1970s, and a substantial number of mAb products have entered the market. However, the majority are still in early-stage development, indicating delays and setbacks in the progression of potential products. Despite this, mAbs are the largest and fastest-growing segment of the biopharmaceutical sector, and account for almost half of the global revenue accrued from this area annually.
The pipeline is highly active, with 2,836 mAbs currently in development. Most are at an early stage of development, with 76% at the Discovery or Preclinical stage. Additionally, there are currently 85 mAb programs in Phase III development, and 22 at the Pre-registration stage, accounting for just under 4% of the total mAb pipeline.
This CBR report provides a comprehensive view of the clinical, R&D, commercial and competitive landscape of mAbs, and assesses key developments in manufacturing and development, covering strategies to combat challenges associated with the use of mAbs in human patients.
-Understand the current status of the field of therapeutic Monoclonal Antibodies, and the relative clinical and commercial success of currently marketed products. -Assess the pipeline for Monoclonal Antibodies split by therapy area, vector type and intervention type, and stage of development. Additionally, a granular assessment of the pipeline is provided across the four major therapy areas for gene therapy: oncology, central nervous system disorders, ophthalmology, and genetic disorders. -Gain a picture of the current competitive landscape, with a detailed breakdown of companies actively involved in the gene therapy pipeline. -Understand the level of involvement in the landscape on the part of big pharma companies, and the extent to how Monoclonal Antibodies fit into the overall portfolios of companies in this field. -Understand the strategic consolidations landscape in Monoclonal Antibodies across the past decade
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: